NewsBenzinga百时美施贵宝与SystImmune的Iza-Bren在3期PANKU-Lung01中期分析中达到主要终点：在EGFR突变非小细胞肺癌中，中位PFS为11.1个月，对比铂类化疗为5.7个月（HR=0.40） 百时美施贵宝与SystImmune的Iza-Bren在3期PANKU-Lung01中期分析中达到主要终点：在EGFR突变非小细胞肺癌中，中位PFS为11.1个月，对比铂类化疗为5.7个月（HR=0.40） Benzinga 2026.10.26 07:54 (GMT+0) Open on Benzinga Other news BMO Capital Initiates Coverage On FirstEnergy with Outperform Rating, Announces Price Target of $50 Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Support for semiconductor stocks could be as much as 15% lower than current levels, says Morgan Stanley Weekly Market Pulse: Where The Puck Will Be Amcor’s Quarterly Earnings Preview: What You Need to Know Apple's Design Team Didn't Want Touchscreen Macs, But Tim Cook and John Ternus Had Other Ideas: Report
Support for semiconductor stocks could be as much as 15% lower than current levels, says Morgan Stanley
Apple's Design Team Didn't Want Touchscreen Macs, But Tim Cook and John Ternus Had Other Ideas: Report
